Articles

Study of patients with lung adenocarcinoma found that patients with KRAS G12C mutation and high PD-L1 expression benefit more from immunotherapy compared with patients with other KRAS mutations. Read More ›

Best Practices: Immune-Related Adverse Event Management in Patients with Advanced NSCLC Treated with  Immune Checkpoint Inhibitors

A study in patients with KRAS G12C-mutated non–small-cell lung cancer with brain metastases found adagrasib to demonstrate intracranial activity while being well tolerated. Read More ›

Study finds circulating tumor DNA reveals disease recurrence before radiographic evidence in patients with non–small-cell lung cancer. Read More ›

Recent study showed that KRAS mutation in patients with non–small-cell lung cancer predicted superior response to first-line immunotherapy. Read More ›

Real-world analysis of mutations in non–small-cell lung cancer showed similar frequencies of common KRAS and EGFR variants in Black and White Americans, but higher EGFR G719S variant was seen in Black Americans. Read More ›

From The Editor October 2022
In the October issue of The Oncology Nurse-APN/PA (TON), we feature a variety of articles aimed at informing and empowering nurses, navigators, and advanced practice providers who work to improve the lives of patients with cancer. Read More ›

As New Jersey’s only National Cancer Institute–designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey, together with RWJBarnabas Health, has a singular focus and mission—to help patients fight cancer. Read More ›

Endocrine therapy after breast-conserving surgery may be the only treatment needed in patients aged ≥55 years with low-grade luminal type A breast cancer, sparing them radiation therapy, including its side effects, financial burden, and inconvenience, according to findings from the single-arm LUMINA clinical trial reported at the 2022 American Society of Clinical Oncology Annual Meeting. Read More ›

In the phase 3 DETERMINATION trial—in which patients with newly diagnosed multiple myeloma were randomly assigned to a standard triplet regimen with and without autologous stem-cell transplantation (ASCT), with all receiving lenalidomide (Revlimid) maintenance therapy until disease progression—patients with ASCT had significantly longer progression-free survival (PFS) versus those who did not, but no difference in overall survival (OS) was observed between the 2 treatment arms. Read More ›

Page 34 of 376


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: